The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Thyroid Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Thyroid Neoplasms


High impact information on Thyroid Neoplasms


Chemical compound and disease context of Thyroid Neoplasms


Gene context of Thyroid Neoplasms

  • Plasma somatostatin activity in medullary cancer of the thyroid [13].
  • Surgery is the only accepted method for a potentially curative treatment of metastatic medullary cancer of the thyroid (MCT) [14].
  • Serum from one patient with cancer of the thyroid, but no sera from non-SCLC patients or normal healthy controls, was positive [15].
  • Only nonmedullary cancer of the thyroid was shown to be statistically more prevalent in HPT patients than in autopsy controls (7% vs 0%, respectively; P < 0.02) [16].
  • Thyroid-carcinoma is one of the extraintestinal manifestations of FAP and particularly women in the age of 25-35 years are at risk according to the literature [17].
  • A commonly found genetic alternation is a point mutation in the BRAF oncogene (BRAF V600E), which is primarily found in papillary thyroid cancer and is associated with more aggressive disease [18].
  • There is intriguing evidence that BRAF mutation testing of papillary thyroid carcinoma might improve the diagnosis, prognostic stratification and treatment of these tumors but large, prospective trials are needed to define the actual clinical impact of these approaches [19].


  1. Type II amiodarone-induced thyrotoxicosis and concomitant papillary cancer of the thyroid. Cattaneo, F. Eur. J. Endocrinol. (2000) [Pubmed]
  2. Expression of C-ERBB2 and P65 genes and their protein products in follicular neoplasms of thyroid gland. Czyz, W., Balcerczak, E., Rudowicz, M., Niewiadomska, H., Pasieka, Z., Kuzdak, K., Mirowski, M. Folia Histochem. Cytobiol. (2003) [Pubmed]
  3. N-cadherin-mediated adhesion and aberrant catenin expression in anaplastic thyroid-carcinoma cell lines. Husmark, J., Heldin, N.E., Nilsson, M. Int. J. Cancer (1999) [Pubmed]
  4. Somatostatin receptor expression in Hürthle cell cancer of the thyroid. Gulec, S.A., Serafini, A.N., Sridhar, K.S., Peker, K.R., Gupta, A., Goodwin, W.J., Sfakianakis, G.N., Moffat, F.L. J. Nucl. Med. (1998) [Pubmed]
  5. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. schmutzler, C., Brtko, J., Winzer, R., Jakobs, T.C., Meissner-Weigl, J., Simon, D., Goretzki, P.E., Köhrle, J. Int. J. Cancer (1998) [Pubmed]
  6. Introduction of p53 induces cell-cycle arrest in p53-deficient human medullary-thyroid-carcinoma cells. Velasco, J.A., Medina, D.L., Romero, J., Mato, M.E., Santisteban, P. Int. J. Cancer (1997) [Pubmed]
  7. Detection of thyroid tumour using a monoclonal 123I anti-human thyroglobulin antibody. Shepherd, P.S., Lazarus, C.R., Mistry, R.D., Maisey, M.N. European journal of nuclear medicine. (1985) [Pubmed]
  8. Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray. Gol Choe, J., Kim, Y.R., Kim, K.N., Choo, H.J., Shin, J.H., Lee, Y.J., Chung, J.K., Kim, M.K. Nuclear medicine communications. (2005) [Pubmed]
  9. Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. Prante, O., Maschauer, S., Fremont, V., Reinfelder, J., Stoehr, R., Szkudlinski, M., Weintraub, B., Hartmann, A., Kuwert, T. J. Nucl. Med. (2009) [Pubmed]
  10. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. Woyach, J.A., Kloos, R.T., Ringel, M.D., Arbogast, D., Collamore, M., Zwiebel, J.A., Grever, M., Villalona-Calero, M., Shah, M.H. J. Clin. Endocrinol. Metab. (2009) [Pubmed]
  11. SKI-606, an Src Inhibitor, Reduces Tumor Growth, Invasion, and Distant Metastasis in a Mouse Model of Thyroid Cancer. Kim, W.G., Guigon, C.J., Fozzatti, L., Park, J.W., Lu, C., Willingham, M.C., Cheng, S.Y. Clin. Cancer Res. (2012) [Pubmed]
  12. Bexarotene via CBP/p300 Induces Suppression of NF-κB-Dependent Cell Growth and Invasion in Thyroid Cancer. Cras, A., Politis, B., Balitrand, N., Darsin-Bettinger, D., Boelle, P.Y., Cassinat, B., Toubert, M.E., Chomienne, C. Clin. Cancer Res. (2012) [Pubmed]
  13. Plasma somatostatin activity in medullary cancer of the thyroid. Neradilová, M., Nĕmec, J., Zamrazil, V., Bednár, J., Pechová, M., Soutorová, M. Oncology (1989) [Pubmed]
  14. Microsurgical neck dissection for metastasizing medullary thyroid carcinoma. Buhr, H.J., Kallinowski, F., Raue, F., Frank-Raue, K., Herfarth, C. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. (1995) [Pubmed]
  15. New serum markers for small-cell lung cancer. II. The neural cell adhesion molecule, NCAM. Vangsted, A., Drivsholm, L., Andersen, E., Bock, E. Cancer Detect. Prev. (1994) [Pubmed]
  16. Increased incidence of thyroid cancer in patients with primary hyperparathyroidism: a continuing dilemma. Fedorak, I.J., Salti, G., Fulton, N., Schark, C., Straus, F.H., Kaplan, E.L. The American surgeon. (1994) [Pubmed]
  17. Thyroid carcinoma as first manifestation of familial adenomatous polyposis. Stigt, J.A., Vasen, H.F., van der Linde, K., van Vliet, A.C. The Netherlands journal of medicine. (1996) [Pubmed]
  18. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Kebebew, E., Weng, J., Bauer, J., Ranvier, G., Clark, O.H., Duh, Q.Y., Shibru, D., Bastian, B., Griffin, A. Ann. Surg. (2007) [Pubmed]
  19. Clinical implications of BRAF mutation in thyroid carcinoma. Puxeddu, E., Durante, C., Avenia, N., Filetti, S., Russo, D. Trends Endocrinol. Metab. (2008) [Pubmed]
WikiGenes - Universities